Expertise in
18
conditions

Dr. Paul L. Crispen

Oncology
Uf Health Urology-Medical Plaza
1549 Gale Lemerand Dr Fl 3, 
Gainesville, FL 
Accepting New Patients
Offers Telehealth
Expertise in
18
conditions
Uf Health Urology-Medical Plaza
1549 Gale Lemerand Dr Fl 3, 
Gainesville, FL 

Overview

Paul Crispen is an Oncologist practicing medicine in Gainesville, Florida.

Dr. Crispen is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

He is actively involved in clinical research, co-authoring 51 peer reviewed articles and participating in 6 clinical trials. Dr. Crispen is currently accepting new patients.

Specialties

Oncology

Licenses

Urology in MN

Hospital Affiliations

Uf Health Shands Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Florida Blue
  • EPO
  • PPO
Freedom Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Uf Health Urology-Medical Plaza
1549 Gale Lemerand Dr Fl 3, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 23, 2026
Intervention Type: Biological, Other
Study Drugs: Bacillus of Calmette-Guerin, Bacillus of Calmette-Guerin Tokyo-172 Strain Solution, Bacillus of Calmette-Guerin Tokyo-172 Strain Vaccine
Study Phase: Phase 3
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Single Arm Phase II Trial of the Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract
A Single Arm Phase II Trial of the Intraoperative Intravesical Instillation of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Mitomycin C
Study Phase: Phase 2
View 5 Less Clinical Trials

51 Total Publications

Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.
Gemcitabine Intravesical System Plus Cetrelimab or Cetrelimab Alone as Neoadjuvant Therapy in Muscle-Invasive Bladder Cancer: SunRISe-4 Primary Analysis and Biomarker Results.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 03, 2025
Similar Doctors
Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

Uf Health Medical Lab-Shands Hospital

1600 SW Archer Rd, 
Gainesville, FL 
 (1.3 miles away)
352-265-0725
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Frederic Kaye is an Oncologist practicing medicine in Gainesville, Florida. Dr. Kaye is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Lung Cancer, and Non-Small Cell Lung Cancer (NSCLC). Dr. Kaye is currently accepting new patients.

Expertise in
7
conditions
Expertise in
7
conditions
Referral may be required

UF Health Bone Marrow Transplant

1515 SW Archer Rd Ste 100, 
Gainesville, FL 
 (1.4 miles away)
352-733-0972
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Cogle is an Oncologist practicing medicine in Gainesville, Florida. Dr. Cogle is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Multiple Myeloma, and Bone Marrow Aspiration. Dr. Cogle is currently accepting new patients.

Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

Uf Health Medical Lab-Shands Hospital

1600 SW Archer Rd, 
Gainesville, FL 
 (1.3 miles away)
352-273-7832
Languages Spoken:
English
See accepted insurances

Nam Dang is an Oncologist practicing medicine in Gainesville, Florida. Dr. Dang is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Large-Cell Immunoblastic Lymphoma.

Frequently Asked Questions about Dr. Paul L. Crispen

How do I make an appointment with Dr. Paul L. Crispen?

You can book an appointment with Dr. Paul L. Crispen by calling their office at 352-265-8240. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul L. Crispen a top-rated expert for Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul L. Crispen is classified as an Elite expert for Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul L. Crispen specialize in?

While Dr. Paul L. Crispen is a Oncology, they have specific expertise in Bladder Cancer, Urothelial Cancer, and Nephrectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Paul L. Crispen participate in research or clinical trials?

Yes. Dr. Paul L. Crispen has published 51 articles and abstracts on conditions like Bladder Cancer. You can view a list of Dr. Paul L. Crispen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul L. Crispen accept my insurance?

Dr. Paul L. Crispen accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 352-265-8240 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Crispen's expertise for a condition
ConditionClose
View All 14 Distinguished Conditions
View All 27 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile